- Home
- ITIC vs ARVN Comparison
ITIC vs ARVN Comparison
Compare ITIC & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITIC
- ARVN
- Stock Information
- Founded
- ITIC 1972
- ARVN 2015
- Country
- ITIC United States
- ARVN United States
- Employees
- ITIC N/A
- ARVN N/A
- Industry
- ITIC Specialty Insurers
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- ITIC Finance
- ARVN Health Care
- Exchange
- ITIC Nasdaq
- ARVN Nasdaq
- Market Cap
- ITIC 440.1M
- ARVN 456.2M
- IPO Year
- ITIC N/A
- ARVN 2018
- Fundamental
- Price
- ITIC $216.49
- ARVN $7.63
- Analyst Decision
- ITIC
- ARVN Buy
- Analyst Count
- ITIC 0
- ARVN 21
- Target Price
- ITIC N/A
- ARVN $20.53
- AVG Volume (30 Days)
- ITIC 62.8K
- ARVN 2.0M
- Earning Date
- ITIC 08-05-2025
- ARVN 07-29-2025
- Dividend Yield
- ITIC 7.50%
- ARVN N/A
- EPS Growth
- ITIC 18.56
- ARVN N/A
- EPS
- ITIC 15.69
- ARVN N/A
- Revenue
- ITIC $261,197,999.00
- ARVN $426,900,000.00
- Revenue This Year
- ITIC N/A
- ARVN $4.26
- Revenue Next Year
- ITIC N/A
- ARVN N/A
- P/E Ratio
- ITIC $13.46
- ARVN N/A
- Revenue Growth
- ITIC 15.27
- ARVN 498.74
- 52 Week Low
- ITIC $174.48
- ARVN $5.90
- 52 Week High
- ITIC $290.40
- ARVN $34.11
- Technical
- Relative Strength Index (RSI)
- ITIC 50.56
- ARVN 53.52
- Support Level
- ITIC $204.58
- ARVN $7.09
- Resistance Level
- ITIC $216.30
- ARVN $7.89
- Average True Range (ATR)
- ITIC 5.21
- ARVN 0.37
- MACD
- ITIC 2.33
- ARVN 0.01
- Stochastic Oscillator
- ITIC 84.05
- ARVN 55.67
About ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.